• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Percutaneous heart valves for valvular heart disease: an updated review of the clinical and cost-effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Albumin versus synthetic plasma volume expanders: a review of the clinical and cost-effectiveness and guidelines for use
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Transcatheter aortic valve implantation: a critical appraisal of a health technology assessment and comparison with a rapid review
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Cognitive behavioural therapy for insomnia in adults: a review of the clinical effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Remote ischemic conditioning: a review of the clinical effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Screening programs for asymptomatic unruptured intracranial aneurysms: review of clinical effectiveness, cost-effectiveness, and evidence-based guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Positive versus negative needleless connectors for central venous lines and peripheral lines: a review of the clinical effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Use of bupropion in patients with depression and the associated risk of seizures: safety
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Fluconazole and pharmaceuticals without inactive ingredients for autism: a review of the clinical effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Gabapentin tablets versus capsules: a review of the evidence regarding appropriate use
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Eden alternative and green house concept of care: review of clinical effectiveness, cost-effectiveness, and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Bifocal lenses under +0.50 diopter: a review of the clinical effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Pre-operative screening and post-operative monitoring in adult patients with obstructive sleep apnea: clinical effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Sternal talon for cardiac surgery patients: a review of the clinical effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Tinnitus retraining therapy: a review of the clinical effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Pre-hospital phlebotomy for patients with urgent conditions: a review of the clinical effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Laser refractive surgery in children: a review of the clinical effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Laparoscopic sleeve gastrectomy: a review of the clinical benefits and harms
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Filtered needles for withdrawing medication from glass ampoules: a review of the cost-effectiveness and incidence of complications
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Periodontal regenerative procedures for patients with periodontal disease: a review of clinical effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Completely-in-the-canal and bone anchored hearing aids: a review of the clinical effectiveness and cost-effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Critical incident stress debriefing for first responders: a review of the clinical benefit and harm
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Cognitive behavioural therapy for patients with addictions: a review of the clinical and cost-effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Atypical antipsychotics for the treatment of schizophrenia: a review of combination therapy and high-dosing strategies
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Tramadol compared with opioids for pain: a review of addiction potential
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Percutaneous heart valve replacement for valvular heart disease: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Cognitive behavioural therapy for post traumatic stress disorder: a review of the clinical and cost-effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for non-hodgkin's lymphoma: a review of the clinical and cost- effectiveness and guidelines
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Use of antipsychotics and/or benzodiazepines as rapid tranquilization in inpatients of mental facilities and emergency departments: a review of the clinical effectiveness and guidelines
2010 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [10th Symposium Health Technology Assessment, Nothing without evidence? 18th-19th March 2010, Cologne]
2010 Andalusian Health Technology Assessment Area (AETSA) [Serum biomarkers panel for detecting early stage ovarian cancer]
2010 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Standards for appropriate use of health technologies. Total hip arthroplasty]
2010 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Efficacy, safety and economic assessment of the percutaneous aortic valve implantation]
2010 Andalusian Health Technology Assessment Area (AETSA) [Oxygen carriers. Production of red blood cells from human embryonic stem cells]
2010 Andalusian Health Technology Assessment Area (AETSA) [Gene expression test for breast cancer Oncotype]
2010 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriate use of diagnostic imaging technologies in acute abdominal pain]
2010 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Cardiac resynchronization therapy. Economic evaluation]
2010 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Development and validation of methods for quality assessment of health technologies assessments reports : assessment of ethical issues in health technologies assessment]
2010 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Laparoscopic surgery in colorectal cancer : quality of life, psychological impact and patient satisfaction]
2010 Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriate use of diagnostic imaging technologies in primary and secondary care : ultrasonography in breast pathology]
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Positron emission tomography for cardiovascular disease: a review of the clinical effectiveness
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Positron emission tomography (PET) in oncology: a systematic review of clinical effectiveness and indications for use
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Second-line therapy for patients with diabetes inadequately controlled on metformin: a systematic review and cost-effectiveness analysis
2010 The Regional Health Technology Assessment Centre (HTA-centrum) [Percutaneuos transcatheter closure of patent foramen ovale]
2010 The Regional Health Technology Assessment Centre (HTA-centrum) [Specialist nurse-led clinic]
2010 The Regional Health Technology Assessment Centre (HTA-centrum) [Transcatheter aortic valve prosthesis implantation (TAVI)]
2010 The Regional Health Technology Assessment Centre (HTA-centrum) [Laparoscopic peritoneal lavage for patients with perforated diverticulitis]
2010 Technology Assessment Unit of the McGill University Health Centre (MUHC) Argon beam coagulation in orthopaedic, urological and thoracic surgery at the MUHC: a brief report
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Ranolazine (Ranexa®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Atazanavir (Reyataz®) capsules
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Sildenafil citrate (Revatio®) solution
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tipranavir (Aptivus®) capsules
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tipranavir (Aptivus®) oral solution
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Epoetin theta (Eporatio®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Olanzapine depot (ZypAdhera)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Cetuximab (Erbitux®) for third-line treatment of patients with KRAS wild-type metastatic colorectal cancer
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Epoetin alfa (Binocrit®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Filgrastim (TevaGrastim®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Filgrastim (Zarzio®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Sildenafil (Revatio®) for the treatment of pulmonary arterial hypertension (WHO functional class II or III) to improve exercise capacity
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®) in combination with other antiretrovirals for the treatment of HIV-1 infection in adults
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Pramipexole prolonged release tablets (Mirapexin®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Epoetin zeta (Retacrit®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Fentanyl (Instanyl®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Enoxaparin (Clexane®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Paclitaxel albumin (Abraxane®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Bortezomib (Velcade®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Plerixafor (Mozobil®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Etanercept (Enbrel®)
2010 Institute of Health Economics (IHE) Evidence on the effectiveness of telerehabilitation applications
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Biologic response modifier agents for adults with rheumatoid arthritis
2010 Canadian Agency for Drugs and Technologies in Health (CADTH) Third-line therapy for patients with type 2 diabetes inadequately controlled with metformin and a sulfonylurea
2010 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Use of telemedicine between Rigshospitalet and Bornholm Hospital: report of a pilot project]
2010 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Vision screening of preschool children]
2010 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Multidisciplinary and multisectoral interventions targeting patients with back pain – a health technology assessment]
2010 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Hip protectors in long-term care]
2010 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Non-medical intervention for people with or without dementia]
2010 Health Technology and Policy Unit (HTPU) An assessment of sleep disordered breathing diagnosis using Level I versus Level III sleep studies
2010 NIHR Health Technology Assessment programme Sorafenib for the treatment of advanced hepatocellular carcinoma
2010 NIHR Health Technology Assessment programme Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection
2010 NIHR Health Technology Assessment programme Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
2010 NIHR Health Technology Assessment programme Alitretinoin for the treatment of severe chronic hand eczema
2010 NIHR Health Technology Assessment programme Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
2010 NIHR Health Technology Assessment programme Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix
2010 NIHR Health Technology Assessment programme Trabectedin for the treatment of advanced metastatic soft tissue sarcoma
2010 NIHR Health Technology Assessment programme Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
2010 National Evidence-based Healthcare Collaborating Agency (NECA) [The disease burden of seasonal influenza and the effectiveness of seasonal influenza vaccination in Korea]
2010 National Evidence-based Healthcare Collaborating Agency (NECA) [The survey and cross-sectional analysis of palliative radiotherapy for bone metastases to facilitate its proper use in cancer patients]
2010 National Evidence-based Healthcare Collaborating Agency (NECA) [Pain relief effects of injection therapy for patients with chronic back pain]
2010 National Evidence-based Healthcare Collaborating Agency (NECA) [Health technology assessment for the effectiveness and safety of human placenta injections]
2010 National Evidence-based Healthcare Collaborating Agency (NECA) [The evidence of korean guidelines for the use of lipid lowering agents: drug utilization review and outcomes research]
2010 National Evidence-based Healthcare Collaborating Agency (NECA) [Effectiveness of treatments for carcinomas of an unknown primary site]
2010 National Evidence-based Healthcare Collaborating Agency (NECA) [Development of empirical treatment guidelines in febrile neutropenic patients on the basis of the Korean data]
2010 National Evidence-based Healthcare Collaborating Agency (NECA) [Drug-eluting stents versus bare-metal stents in acute myocardial infarction]
2010 National Evidence-based Healthcare Collaborating Agency (NECA) [Outcomes of therapeutic modalities for post-partum hemorrhage]
2010 National Evidence-based Healthcare Collaborating Agency (NECA) [A study of the effectiveness of self-care interventions for subclinical and mild depression]
2010 National Evidence-based Healthcare Collaborating Agency (NECA) [Korean guidelines for the prophylactic use of white blood growth factors]
2010 Norwegian Knowledge Centre for the Health Services (NOKC) [Effect of interventions to improve the quality of health services for ethnic minorities]
2010 University of York Alternatives to inpatient admission for adolescents with eating disorders
2010 Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR) Innovative radiation treatment in cancer: IGRT/IMRT (Image Guided Radiation Therapy /IntensityModulated Radiation Therapy)